The initial goal for retinal gene therapies was simply to arrest the progression of vision loss. Beacon Therapeutics' treatment demonstrates a significant evolution, not just preserving existing vision but actively improving it. This marks a paradigm shift in therapeutic ambition and patient outcomes for degenerative eye diseases.

The FDA issued Complete Response Letters for both REGENXBIO's gene therapy and DISC Medicine's oral drug, signaling high scrutiny for accelerated approvals. The agency specifically cited concerns over the relevance of surrogate endpoints and required more robust clinical trial data, highlighting the risks of relying on non-traditional approval pathways.

Beacon Therapeutics' success is attributed to using codon optimization to deliver a full-length protein. This contrasts with a competitor's failed trial that used a truncated version, proving that painstaking early scientific work to ensure delivery of the complete protein is critical for clinical success in gene therapy.

For its alpha-1 antitrypsin deficiency program, Beam aligned with the FDA on an accelerated approval pathway based on a surrogate endpoint: restored alpha-1 protein levels. This strategy allows for faster market entry, with a longer-term confirmatory trial measuring clinical outcomes like lung and liver function running in parallel.

Biogen is proceeding with its anti-tau therapy Duranderson, even though it missed its primary endpoint. The rationale is that the observed slowing of cognitive decline on secondary measures (26-50%) is comparable, or even slightly better than, the results of already-approved anti-amyloid antibodies. This strategy shows how a technically 'failed' trial can find a path forward by meeting the efficacy bar set by existing treatments.

While the FDA avoids providing an explicit number, analysis of previously approved drugs in this indication reveals a clear benchmark. A complete response (CR) rate of "about two-thirds" in the pivotal trial is the unofficial target companies like enGene must hit to be considered in the approvable range.

The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.

During NervGen's End-of-Phase 2 meeting, the FDA emphasized understanding the drug's real-world impact on a patient's daily life, not just the quantitative results of the primary endpoint. This signals a regulatory shift towards a more holistic, patient-centric view of therapeutic benefit in areas of high unmet need.

Ocular Therapeutix's trial prioritized a primary endpoint designed to satisfy FDA requirements for a superiority label—a key regulatory win. However, the CEO stresses that clinicians use different metrics like OCT fluid, where their drug "easily beat Eylea." This highlights a crucial strategy: separate the endpoint needed for approval from the data that drives physician adoption.